{{$DoctorName}} @if(isset(session()->get('doctor')['vCentralCode'])) {{session()->get('doctor')['vCentralCode']}} @endif
@if(isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{$ActivityTypeName}}

{{$ActivityName}}

@csrf
@if(isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
Gemtaz Survey
{{--

A retrospective, cross-sectional,--}} {{-- observational survey study to understand the role of Sodium Hyaluronate eye drops in--}} {{-- management of dry eye disease

--}}
    {{--1 --}}
  1. In your clinical practice, what percentage of your Gemcitabine prescriptions are in the below mentioned indications? *
    2. Lung cancer
    %
    Pancreatic cancer
    %
    Breast cancer
    %
    Ovarian cancer
    %
    %
    {{--2 --}}
  2. In your clinical practice, which of the following Gemcitabine dosing schedule do you commonly prescribe in your NSCLC patients? *

    3. {{--3 --}}
  3. Do you feel, reconstitution process of conventional chemotherapy is complex and increases risk to healthcare professionals? *

    4. {{--4 --}}
  4. According to data published by a cancer center in India, in a sample size of 500 patients, *
    • Medication errors were reported in 41.6% of patients
    • 21% of medication errors were related to administration and drug reconstitution errors [56%] was the most common reason
    • How frequently do drug reconstitution errors occur at your institute? *

    {{--
    --}} {{--
    --}} {{--
  5. According to data published by a cancer center in India, in a sample--}} {{-- size of 500 patients, *--}} {{--
    6. --}} {{--
    --}} {{--

    --}} {{-- --}} {{-- --}} {{--

    --}} {{--

    --}} {{-- --}} {{-- --}} {{--

    --}} {{--
    --}} {{--
    --}} {{--
    --}} {{-- --}}{{--5 --}} {{--
    --}} {{--
  6. How frequently do drug reconstitution errors occur at your--}} {{-- institute? *--}} {{--
    7. --}} {{--
    --}} {{--

    --}} {{-- --}} {{-- --}} {{--

    --}} {{--

    --}} {{-- --}} {{-- --}} {{--

    --}} {{--

    --}} {{-- --}} {{-- --}} {{--

    --}} {{--

    --}} {{-- --}} {{-- --}} {{--

    --}} {{--
    --}} {{--
    --}} {{--6 --}}
  7. Huge patient load at hospitals can increase the wait time for drug administration. *

    8. {{--7 --}}
  8. Chemo reconstitution can sometime lead to accidental needle prick injury. *

    9. {{--8 --}}
  9. Accidental breakage/spillage of vial can sometime lead to drug exposure *

    10. {{--9 --}}
  10. Chances of microbial contamination are slightly higher with conventional vials. *

    11. {{--10 --}}
  11. Reconstitution is a time-consuming process considering the high patient load in day care. *

    12. {{--11 --}}
  12. Do you think that a Ready to Administer technology for chemotherapy administration can make the drug reconstitution process safe and easy? (Select one or more options) *

    13. {{--12 --}}
  13. From your clinical experience, which of the following benefits of Gemtaz Infusmart do you find most helpful in your practice? Rank them in order of your preference [1-Highest preferred benefit, 4-least preferred benefit] *
    14. Less chances of contamination
    Neutral pH
    No accidental drug exposure
    Time saving
    {{--13 --}}
  14. From your clinical practice, in what percentage of patients do you recommend the following doses of Gemcitabine? *
    15. 1000mg
    %
    1200mg
    %
    1400mg
    %
    1600mg
    %
    1800mg
    %
    Any other dose
    mg
    %
    Any other dose
    mg
    %
    {{--14 --}}
  15. Did you face any challenge while administering Gemtaz Infusmart to the patient? *

    16. {{--15 --}}
  16. As you are aware, the pH of Gemcitabine vials is acidic after reconstitution. Do your patients also experience or complain of injection site pain while administering conventional gemcitabine? *

    17. {{--16 --}}
  17. How do you perceive the price of Gemtaz Infusmart compared to other brands in the market? *

    18. {{--17 --}}
  18. Does Infusmart technology enhance the quality of patient care? *